Skip to main content

Table 1 Subjects at screening visit, mean ± standard deviation or tally

From: A randomized feasibility trial of medium chain triglyceride-supplemented ketogenic diet in people with Parkinson's disease

 

Ketogenic Diet (n = 7)

Standard Diet (n = 9)

Age (years)

67.3 ± 7.5

67.1 ± 4.5

Sex Female

2 (28.6%)

5 (55.6%)

White

6 (85.7%)

7 (77.8%)

Asian

1 (14.3%)

1 (11.1%)

Race not reported

 

1 (11.1%)

Years since PD diagnosis

15.2 ± 9

10.3 ± 5.3

LEDD (mg)

655 ± 340

738 ± 306

Bilateral STN

2 (28.6%)

4 (44.4%)

H&Y

2.5 ± 0.4

2.4 ± 0.4

NMSS

48 ± 19

44 ± 18

Waist circumference (cm)

91.4 ± 13.7

100.4 ± 9.3

Blood glucose (mg/dL)

92.6 ± 9.4

93.1 ± 10.3

Insulin (uIU/L)

8.8 ± 5.2

10.6 ± 4.2

Triglyceride (mg/dL)

82.2 ± 24.4

109.6 ± 35.2

HDL (mg/dL)

61.7 ± 16

46.3 ± 17.0

Metabolic syndrome

4 (57%)

2 (22%)

BMI (kg/m2)

29.5 ± 5.2

25.7 ± 2.8

Baseline carb %

54%

44%

  1. Metabolic syndrome: Six subjects met the criteria for metabolic syndrome according to the AHA/NHLBI criteria (2004) and/or insulin resistance according to the threshold homeostasis model assessment of insulin resistance (HOMA-IR) > 2.0 [32].
  2. Bilateral STN Received deep brain stimulation of bilateral subthalamic nucleus, H&Y Hoehn and Yahr Scale score, LEDD Daily Levodopa equivalent dose, NMSS MDS Non-Motor Symptom Scale.